Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Product availability issue? 399 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 399 reports of Product availability issue have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.3% of all adverse event reports for SECUKINUMAB.

399
Reports of Product availability issue with SECUKINUMAB
0.3%
of all SECUKINUMAB reports
6
Deaths
61
Hospitalizations

How Dangerous Is Product availability issue From SECUKINUMAB?

Of the 399 reports, 6 (1.5%) resulted in death, 61 (15.3%) required hospitalization, and 18 (4.5%) were considered life-threatening.

Is Product availability issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 399 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Product availability issue?

RUXOLITINIB (2,142) LISDEXAMFETAMINE DIMESYLATE (1,530) CERTOLIZUMAB PEGOL (1,381) VEDOLIZUMAB (636) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (610) METHYLPHENIDATE (444) BIMEKIZUMAB-BKZX (364) LACOSAMIDE (359) BRIVARACETAM (324) SACUBITRIL\VALSARTAN (283)

Which SECUKINUMAB Alternatives Have Lower Product availability issue Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Product availability issue Reports All Drugs Causing Product availability issue SECUKINUMAB Demographics